Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma

Liu,Chibo; Pan,Chunqin; Liang,Yong

doi:10.3892/etm.2012.515

Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma

Authors:
- Chibo Liu
- Chunqin Pan
- Yong Liang
View Affiliations

Affiliations: Department of Clinical Laboratory, Taizhou Municipal Hospital, Taizhou, Zhejiang, P.R. China, Department of Tumorology, Taizhou Municipal Hospital, Taizhou, Zhejiang, P.R. China
Published online on: March 14, 2012 https://doi.org/10.3892/etm.2012.515
Pages: 1005-1009

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to screen for possible serum biomarkers for gastric adenocarcinoma. Surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS) was used to screen serum samples from 109 cases of gastric adenocarcinoma and 106 control subjects (60 healthy subjects, 30 patients with chronic superficial gastritis and 16 cases of chronic atrophic gastritis). The differentially expressed protein peaks were selected and isolated using high performance liquid chromatography (HPLC) and processed with enzyme prior to liquid chromatography-mass spectrometry tandem mass spectrometry (LC-MS/MS) analysis and data mining with software XCalibur program components BioWorks 3.2. Among the gastric cancer cases, three differentially expressed protein peaks were selected as potential serum biomarkers: the m/z peaks at 5,906.5 showed increased expression (8.53±4.33 in the cancer group, and 0.88±0.31 in the control group); the m/z peaks at 6,635.7 and 8,716.3 showed decreased expression (6.54±2.44 and 0.93±0.29, respectively, in the cancer group and 17.56±4.43 and 2.16±0.98, respectively, in the control group) (P<0.01). The m/z peaks at 5,906.5, 6,635.7 and 8,716.3, were identified as fibrinogen α-chain, apolipoprotein A-II and apolipoprotein C-I. The combined use of the three biomarkers distinguished the cancer group patients from the control group samples at a sensitivity of 93.85% (61/65) and a specificity of 94.34% (50/53). In conclusion, fibrinogen α-chain, apolipoprotein A-II and apolipoprotein C-I were identified as potential markers for gastric cancer and appear to have diagnostic value for clinical applications.

View Figures

View References

1.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
3.	Tseng CW, Yang JC, Chen CN, et al: Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics. 11:2423–2439. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Kobayashi Y, Niwa Y, Tajika M, et al: Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer. Hepatogastroenterology. 57:1631–1634. 2010.PubMed/NCBI
5.	Yang S and Chung HC: Novel biomarker candidates for gastric cancer. Oncol Rep. 19:675–680. 2008.PubMed/NCBI
6.	Chan DC, Chen CJ, Chu HC, et al: Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol. 14:84–93. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Poon TC: Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics. 4:51–65. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Cho WC: Research progress in SELDI-TOF MS and its clinical applications. Sheng Wu Gong Cheng Xue Bao. 22:871–876. 2006.(In Chinese).
9.	Clarke CH, Buckley JA and Fung ET: SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med. 43:1314–1320. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Liu C: The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol. 2011:2458212011.PubMed/NCBI
11.	Caffrey RE: A review of experimental design best practices for proteomics based biomarker discovery: focus on SELDI-TOF. Methods Mol Biol. 641:167–183. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Kristina G, Radomir P, Eva B, et al: When one chip is not enough: augmenting the validity of SELDI-TOF proteomic profiles of clinical specimens. Lab Chip. 9:1014–1017. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Liu W, Gao X, Cai Q, et al: Identification of novel serum biomarkers for gastric cancer by magnetic bead. Front Biosci (Elite Ed). 2:961–971. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Huang Q, Chen W, Wang L, Lin W, Lin J and Lin X: Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology. J Cancer Res Clin Oncol. 134:1219–1227. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Umemura H, Togawa A, Sogawa K, et al: Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol. 46:577–585. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Wang J, Yu JC, Kang WM and Ma ZQ: Treatment strategy for early gastric cancer. Surg Oncol. Jan 21–2011.(Epub ahead of print).
17.	Saka M, Morita S, Fukagawa T and Katai H: Present and future status of gastric cancer surgery. Jpn J Clin Oncol. 41:307–313. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Cho WC: Proteomics technologies and challenges. Genomics Proteomics Bioinformatics. 5:77–85. 2007. View Article : Google Scholar
19.	Cho WC: Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer. 6:252007. View Article : Google Scholar : PubMed/NCBI
20.	Lei L, Wang XJ, Zheng ZG, et al: Identification of serum protein markers for breast cancer relapse with SELDI-TOF MS. Anat Rec (Hoboken). 294:941–944. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Felix K, Fakelman F, Hartmann D, et al: Identification of serum proteins involved in pancreatic cancer cachexia. Life Sci. 88:218–225. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Liu L, Liu J, Wang Y, et al: A combined biomarker pattern improves the discrimination of lung cancer. Biomarkers. 16:20–30. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Hogdall E, Fung ET, Christensen IJ, et al: Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin Appl. 4:940–952. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Gemoll T, Roblick UJ, Auer G, Jornvall H and Habermann JK: SELDI-TOF serum proteomics and colorectal cancer: a current overview. Arch Physiol Biochem. 116:188–196. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Konstantopoulos K and Thomas SN: Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng. 11:177–202. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Costantini V and Zacharski LR: The role of fibrin in tumor metastasis. Cancer Metastasis Rev. 11:283–290. 1992. View Article : Google Scholar : PubMed/NCBI
27.	Vanhollebeke B and Pays E: The function of apolipoproteins L. Cell Mol Life Sci. 63:1937–1944. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Ashe PC and Berry MD: Apoptotic signaling cascades. Prog Neuropsychopharmacol Biol Psychiatry. 27:199–214. 2003. View Article : Google Scholar
29.	Engwegen JY, Helgason HH, Cats A, et al: Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol. 12:1536–1544. 2006.
30.	Fan Y, Wang J, Yang Y, et al: Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol. 136:1243–1254. 2010. View Article : Google Scholar : PubMed/NCBI